MCRB
Seres Therapeutics, Inc.
+0.06 (+1.43%)4.27USD14.5K成交股數42.4M市值–本益比(近四季)22.5股價營收比–營收年增(近四季)2026-11-04下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 736K | 358K | 438K | 351K | 0.00 | 0.00-100% | 0.00-100% | 0.00-100% | 0.00 | −126M | 310K | 126M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 9.1M | 13.2M | 11.7M | 12.6M | 12.9M | 11.8M | 16.5M | 15.8M | 19.5M | 1.7M | 25.2M | 46.8M |
| 銷售管理費用 | 7.1M | 8.1M | 7.5M | 9.5M | 10.3M | 11.9M | 12.7M | 13.1M | 14.9M | 7.5M | 19.4M | 28.1M |
| 營業利益 | −21.3M-15% | −20.9M-23% | −19.4M-34% | −22.5M-22% | −24.9M-28% | −27.2M-79% | −29.2M-35% | −28.9M-158% | −34.4M | −129M | −44.6M | 49.5M |
| 營業利益率 | -2,890.4% | -5,839.9% | -4,424.0% | -6,403.7% | – | – | – | – | – | 102.5% | -14,382.6% | 39.2% |
| 稅後淨利 | 4.6M-123% | −19.9M-161% | −15.3M-117% | 8.2M-125% | −19.9M-51% | 32.7M-179% | 88.8M-286% | −32.9M-171% | −40.1M | −41.2M | −47.9M | 46.6M |
| 淨利率 | 622.4% | -5,562.3% | -3,501.1% | 2,337.3% | – | – | – | – | – | 32.7% | -15,436.8% | 36.8% |
| 稀釋 EPS | 0.47-121% | -2.08-155% | -1.78-115% | 0.94-122% | -2.27-59% | 3.75-122% | 11.63-3243% | -4.34-1306% | -5.49 | -17.19 | -0.37 | 0.36 |
| 稀釋股數 | 9.7M | 9.6M | 8.9M | 8.8M | 8.7M | 8.7M | 7.6M | 7.6M | 7.3M | 6.4M | 128M | 130M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 15.6M | 29.8M | 45.8M | 47.6M | 45.4M | 58.8M | 66.8M | 71.2M | 111M | 128M | 170M | 230M |
| 應收帳款 | 274K | 233K | 157K | 351K | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | 53.0M | 42.0M | 29.6M | 18.5M | 5.3M |
| 總資產 | 102M | 118M | 138M | 143M | 144M | 164M | 179M | 322M | 341M | 359M | 368M | 406M |
| 有息負債 | – | – | – | – | – | – | – | 110M | 110M | 110M | 110M | 110M |
| 總負債 | 67.1M | 91.1M | 94.0M | 99.8M | 111M | 114M | 155M | 409M | 401M | 403M | 383M | 384M |
| 股東權益 | 34.5M | 26.5M | 44.2M | 43.7M | 33.0M | 50.5M | 23.9M | −87.1M | −59.7M | −44.9M | −15.1M | 22.6M |
| 負債比 | 66.0% | 77.5% | 68.0% | 69.5% | 77.1% | 69.3% | 86.6% | 127.1% | 117.5% | 112.5% | 104.1% | 94.4% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | −38.8M | 1.2M | 18.0M | 59.9M | 120M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −16.4M-161% | – | – | – | 26.9M | – | – | −35.2M | – | – | – |
| 資本支出 | – | 0.00 | – | – | – | 34K | – | – | 62K | – | – | – |
| 自由現金流 | – | −16.4M-161% | – | – | – | 26.9M | – | – | −35.3M | – | – | – |
| 折舊攤銷 | 670K | 781K | 954K | 1.0M | 1.1M | 1.1M | 1.4M | 1.4M | 1.6M | 1.6M | 1.7M | 1.5M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -4,569.8% | – | – | – | – | – | – | – | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 789K | – | 5.7M | 721.9% | 0.64 | 865K |
| FY2024 | 0.00 | – | 136K | –% | 0.00 | −149M |
| FY2023 | 0.00 | -100.0% | −114M | –% | -17.77 | −125M |
| FY2022 | 7.1M | -95.0% | −250M | -3,509.5% | -2.31 | −239M |
| FY2021 | 144M | +1109.2% | −65.6M | -45.6% | -0.72 | −2.9M |
| FY2020 | 11.9M | -56.2% | −89.1M | -749.2% | -1.12 | −94.2M |
| FY2019 | 27.2M | +1.0% | −70.3M | -258.5% | -1.24 | −77.5M |
| FY2018 | 26.9M | – | −98.9M | -367.6% | -2.43 | −64.8M |